Mangone Lucia, Marinelli Francesco, Bisceglia Isabella, Braghiroli Maria Barbara, Damato Angela, Pinto Carmine
Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Via Amendola 2, Reggio Emilia, Italy.
Medical Oncology Unit, Comprehensive Cancer Center, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Viale Risorgimento 80, Reggio Emilia, Italy.
Front Oncol. 2022 Oct 31;12:982461. doi: 10.3389/fonc.2022.982461. eCollection 2022.
The aim of this study is to present the 5-year relative survival by stage of breast and colorectal cancer patients in a northern Italian province. For the period 2013-2015, cases were selected from the Reggio Emilia Cancer Registry. Breast cancer patients were divided into 3 age groups: <45, 45-74 (the target screening population) and 74+. Colorectal cancers patients were classified into <50, 50-69 (the target screening population), and over 69 years. Carcinomas and unknown stage were both excluded from the survival analyses. The five-year relative survival was estimated using the Pohar Perme method. During the period examined, 1,450 breast cancers and 992 colorectal cancer cases were registered. Analyzing in detail the patients with breast cancer for the entire 2013-2015 period, we noted that 50.4% were in stage I, 33.6% in stage II, 10.8% in stage III and 3.8% in stage IV. The stage was unknown in only 1.3% of patients (19 cases). The stage data of patients with colorectal cancer showed 24.5% were in stage I, 26.1% in stage II, 23.4% in stage III, and 24.6% in stage IV, and 1.4% unknown. Breast cancer 5-year survival was 100%, 89.7%, 71.4%, and 29.1% for stages I, II, III and IV, respectively and for colon cancer 96.7%, 83.4%, 70.8% and 16.2%, respectively.The presence of cancer screening, associated with effective treatments, account for the high survival rate of early-stage breast and colon cancers.
本研究旨在呈现意大利北部某省乳腺癌和结直肠癌患者按分期计算的5年相对生存率。在2013 - 2015年期间,病例选自雷焦艾米利亚癌症登记处。乳腺癌患者分为3个年龄组:<45岁、45 - 74岁(目标筛查人群)和74岁以上。结直肠癌患者分为<50岁、50 - 69岁(目标筛查人群)和69岁以上。生存分析排除了癌肉瘤和分期不明的病例。采用波哈尔·佩尔梅方法估计5年相对生存率。在研究期间,共登记了1450例乳腺癌和992例结直肠癌病例。详细分析2013 - 2015年整个期间的乳腺癌患者,我们注意到50.4%为I期,33.6%为II期,10.8%为III期,3.8%为IV期。仅1.3%的患者(19例)分期不明。结直肠癌患者的分期数据显示,24.5%为I期,26.1%为II期,23.4%为III期,24.6%为IV期,1.4%分期不明。乳腺癌I期、II期、III期和IV期的5年生存率分别为100%、89.7%、71.4%和29.1%,结肠癌分别为96.7%、83.4%、70.8%和16.2%。癌症筛查与有效治疗相结合,使得早期乳腺癌和结肠癌的生存率较高。